ea0089c3 | Clinical – Chemo/SSA/Biologics | NANETS2022
Clarke, MD, MS Callisia N.
, Cockrum, BSci, PharmD, RPh Paul
, Beveridge, MSc, PhD Thomas J.R.
, Jerry, MS Michelle
, McMorrow, BS Donna
, Thu Tran, PharmD Anh
, Phan, MD Alexandria T.
Background: LA-SSA therapy, including octreotide long-acting release (LAR) and lanreotide depot (LAN), is recommended as first-line therapy for treatment of unresectable or metastatic NETs. Understanding treatment sequencing and dosing patterns of LA-SSAs is essential for clinical decision-making to provide value-based management of NET for both the patients and healthcare system. This study describes treatment patterns of LA-SSA therapy among privately insured patients with N...